Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 1,196.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 336,237 shares of the medical equipment provider's stock after buying an additional 310,301 shares during the quarter. Assenagon Asset Management S.A. owned 0.49% of Lantheus worth $32,817,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Kestra Investment Management LLC purchased a new stake in shares of Lantheus in the fourth quarter valued at approximately $27,000. Summit Securities Group LLC purchased a new stake in shares of Lantheus in the fourth quarter valued at approximately $37,000. Parkside Financial Bank & Trust increased its position in shares of Lantheus by 49.4% in the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after buying an additional 280 shares in the last quarter. UMB Bank n.a. increased its position in shares of Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock valued at $92,000 after buying an additional 381 shares in the last quarter. Finally, 1620 Investment Advisors Inc. purchased a new stake in shares of Lantheus in the fourth quarter valued at approximately $125,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at $11,445,207.20. The trade was a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director now directly owns 318,650 shares of the company's stock, valued at approximately $24,481,879.50. This trade represents a 7.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts recently commented on LNTH shares. B. Riley dropped their price target on Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a research report on Friday, March 21st. Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. Finally, Truist Financial dropped their price target on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $132.67.

Lantheus Price Performance

Shares of LNTH stock traded down $2.31 during midday trading on Friday, hitting $77.83. The company had a trading volume of 1,068,722 shares, compared to its average volume of 1,013,524. Lantheus Holdings, Inc. has a 52-week low of $73.11 and a 52-week high of $126.89. The stock has a market cap of $5.38 billion, a price-to-earnings ratio of 12.95 and a beta of 0.11. The company's 50 day simple moving average is $88.82 and its 200 day simple moving average is $91.39.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same quarter last year, the firm earned $1.69 earnings per share. The firm's quarterly revenue was up .8% compared to the same quarter last year. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.